To elucidate the mechanisms involved in altering serum 3,3',5'-triiodothyronine (rT3) levels with absolute or relative low 3,5,3'-triiodothyronine (T3) states in man, agents capable of lowering circulating T3 levels were sequentially administered to six euthyroid subjects. These agents included propylthiouracil (PTU) (300 mg/6 h X 5 d), dexamethasone (DEX) (2 mg/6 h X 5 d), and thyroxine (T4) (3.0 mg load and 0.3 mg/d X 5 d). 1125I] rT3 clearance rates and rT3 production rates were then determined. Increased serum rT3 levels and rT3/T4 values occurred with both PTU and DEX as compared with control, while T4 increased serum rT3 but did so without changing rT3/T4 values. The rT3 clearance rate was significantly decreased by PTU without altering production rate, while DEX increased the rT3 production rate without altering the rT3 clearance rate. T4 administration did not change rT3 clearance but proportionately increased rT3 production. These responses indicate that circulating rT3 predominantly originates from a non-PTU inhibitable deiodinase enzyme system located in extrahepatic tissues. This enzyme system appears to have a high capacity and low affinity for T4 and can be stimulated by DEX administration.
Introduction
The peripheral metabolism of thyroxine (T4)' in man is a complex process appearing to be of central importance in the regulation of thyroid hormone activation and action. Although this process is concerned with the generation of the active metabolite 3,5,3'-triiodothyronine (T3) via outer ring or 5'-monodeiodination ofT4, an approximately equal portion of T4 is also deiodinated to the apparently inactive metabolite 3,3',5'-triiodothyronine (rT3) by inner ring or 5-deiodination. Further, it is estimated that the combined generation ofT3 and rT3 from T4 accounts for 80% of T4 disposal in the euthyroid state while the remaining 20% apparently occurs by a variety of alternate pathways including sulfate and glucuro-pylthiouracyl; T4, thyroxine; rT3, 3,3',5'-triiodothyronine; T3, 3,5,3'-triiodothyronine.
nide conjugation, conversion to acetic acid analogues, and ether-link cleavage (1) (2) (3) (4) .
Alterations in the normal pattern of peripheral T4 metabolism commonly occur in response to a variety of nonthyroidal illnesses, fasting, administration of various pharmacologic agents as well as with T4 excess states (5) (6) (7) (8) (9) (10) (11) (12) . In all but the latter case, there is either an absolute or relative fall in T3 production and, in turn, serum T3 levels. Concomitant with the fall in serum T3 levels, there is usually a reciprocal increase in circulating rT3 values suggesting a shift from activating to inactivating pathways for peripheral T4 metabolism. However, in those conditions thus far studied, such as nonthyroidal illness, liver disease, and fasting, the rise in serum rT3 values has been found by tracer kinetic studies to be secondary to a decrease in rT3 clearance rather than by an increase in the level of rT3 production (13) (14) (15) (16) . Since these are also conditions associated with reduced T3 production, it suggests that there must be a compensatory increase in T4 metabolism by the alternate pathways.
The purpose of the present study is to determine whether various pharmacologic agents, which have been previously described as producing absolute or relative reductions in serum T3 levels, raise rT3 values by increasing its production or decreasing its clearance or both. The agents tested included propylthiouracil (PTU), dexamethasone (DEX), and T4 (7) (8) (9) (10) (11) (12) . If the changes observed are similar in character to those previously described in nonthyroidal illnesses and fasting, it can be inferred that a common mechanism for elevating serum rT3 levels may be involved in all low T3 states. Further, the administration of these agents may allow a more precise estimation of the magnitude and character of the alternate pathways for T4 disposal.
Methods
Six healthy euthyroid male subjects, ages 24-56 yr, participated in this study. Written informed consent was obtained from each volunteer before the initiation of the protocol. All studies were approved by the Institutional Review Board of the Los Angeles County/USC Medical Center and conducted on the General Clinical Research Center ofthat institution.
Protocol. Subjects underwent a series of four studies over a period of 3 wk as outlined in Fig. 1 . I d before and daily throughout the duration of the study, each subject received 10 drops of a saturated solution of potassium iodide orally to prevent thyroidal uptake and recycling of radioiodine. At 0900 hours on the morning of each study period, the subject was given I liter of water orally to insure adequate urine flow. A (±SEM, n = 6).
Selected serum and urine thyronine Sep-Pak eluates were analyzed by HPLC. Separation of the radiothyronines was accomplished on a 240, 300, 360, 600, and 720 mt after each injection to determine the reverse-phase C 18 column (Water Associates) run with a gradient sysdisappearance pattern of the labeled rT3. Serial urine samples were tern ranging from 16 to 26% THF:NH4Ac and then purged of any collected in 2-liter plastic bottles containing 2 ml of25% human serum remaining radiothyronines with a 50% THF:NH4Ac wash. Standards albumin (Travenol Laboratories, Inc., Glendale, CA) to bind and staof labeled rT3, 3,3'-diiodothyronine (3, 3 '-T2), 3,5,3'-triiodothyronine bilize excreted thyronines. The collections were made every 2 h for the sulfate, 3,3'-T2 diiodothyronine sulfate and iodide were run concomifirst 6 h and then every 6 h for the next 24 h to estimate the total tantly in the appropriate media to identify the radiothyronines in the deiodination of the tracer rT3. This 30-h urinary collection period was patient sample. utilized as > 90% of the total 125I activity excreted had been recovered.
Serum total T4, T3, rT3, and TSH concentrations were determined All urine samples were refrigerated during the collection period and by previously described radioimmunoassay procedures (6) . A highly stored for processing. All blood samples were allowed to clot fully at specific rT3 antibody kindly provided by Dr. Theo J. Visser (Rotterroom temperature before the serum was separated and stored at dam, The Netherlands) was employed in the rT3 radioimmuno--20'C for processing. After the completion of the control period, the assay (18). subjects were given sequentially PTU (300 mg every 6 h), DEX (2 mg Statistical analysis was by paired t test and results reported as every 6 h), and then an oral 3.0 mg T4 load followed by a maintenance meantSEM.
dose (0.30 mg every day). Each study agent was administered for a 3-d period before the rT3 tracer studies to allow peripheral thyronine status to approach a new equilibrium. At least 3 d were allowed between each study period to minimize the influence of the previous study agent.
Sample processing. To separate labeled thyronines from radioiodine and iodoproteins, the serum samples were processed using C 18
Sep-Pak cartridges (Waters Associates, Milford, MA). Each Sep-Pak cartridge was activated with 10 ml of a 50% tetrahydrofuran: 20 mM ammonium acetate (THF:NH4Ac) solution followed by 10 ml of 10% THF:NH4Ac. Serum samples, volumes ranging from 3.0 to 5.0 ml, were incubated for 3 min with an equal volume of 0.2 N NaOH and passed through an activated Sep-Pak. This was followed by a 5.0 ml wash of 10% THF:NH4Ac to eliminate radioiodide. The bound radioiodothyronines were then eluted from the Sep-Pak with 4 ml of 50% THF:NH4Ac and collected in 12 X 75 mm culture tubes, and counted on a dual channel gamma counter (TM Analytic, Elk Grove Village, IL). The average recovery of [1251]rT3 from serum was 85±1.1% (±SEM, n = 6). Less than 1% of the radioiodide, as assessed by sodium '3'I studies, was recovered in the thyronine elution fraction (n = 6). Greater than 99% of the iodoproteins, as assessed by radiolabeled albumin studies, were recovered in the void volume (n = 6). After appropriate corrections for recovery, individual serum tracer rT3 disappearance curves were analyzed by noncompartmental analysis (13). Table I . Treatment with PTU did not change the serum T3/T4 ratio as compared to control. DEX administration also did not decrease the T3/T4 ratio despite significantly lowering T3 values, while oral T4 loading did decrease the T3/T4 ratio. This latter finding is consistent with the previously reported data showing an "autoregulatory" decrease in T4 conversion to T3 in man in high T4 states (1 1, 12) . Both PTU and DEX significantly increased serum rT3/T4 ratios, while no significant influence on rT3/T4 was found with the oral T4 load as compared to control. The mean serum tracer rT3 disappearance curves in each study period are plotted in Fig. 2 . Only PTU significantly altered the disappearance pattern of tracer rT3. Estimates of rT3 metabolic clearance rates are summarized in Table II . PTU administration decreased the clearance of tracer rT3 while treatment with DEX and oral T4 load had no significant influence on clearance as compared to control. PTU did not alter the rT3 production rate while DEX administration increased the daily production rate of rT3 as compared to control. Oral T4 administration substantially increased the daily rT3 production rate.
Results
The mean serum rT3 clearance and production rates as calculated by noncompartmental analysis were compared to the mean serum clearance and appearance rates generated by compartmental analysis. Noncompartmental analysis slightly overestimated serum clearance values in all groups as compared with those generated by compartmental analysis (8.8% in normals, 4.5% with PTU, 2.9% with DEX, and 7.8% with T4). A similar pattern was seen when mean serum production 100 r rates calculated by each method were compared (6.3% in normals, 6.3% with PTU, 4.3% with DEX, and 8.3% with T4).
Estimates of total deiodination of tracer rT3 in each study group are shown in Fig. 3 . The fraction of rT3 undergoing deiodination decreased both with PTU administration and after the oral T4 load while treatment with DEX had no effect as compared to control.
Some of the urine samples, after Sep-Pak concentration, were further analyzed by reverse-phase HPLC. Note that the passage of urine through the Sep-Pak eliminated any free radioiodide present. Fig. 4 for comparison. Despite the intravenous administration oflabeled rT3, no labeled rT3 was detected in the urine. The major urinary peak co-migrated with the 3,3'-T2 standard and is presumably the primary deiodinative product of rT3, 3,3'-T2. Interestingly, a peak migrating just before the T3SO4 standard was found suggesting formation of an rT3 conjugate. In this context, Mol and Visser (2) reported that the sulfate of rT3 elutes before T3 sulfate when using a similar mobile phase.
In selected serum extracts, HPLC analysis revealed a single peak, which comigrated with the injected rT3 tracer (data not shown). Less than 10% of labeled rT3 added to urine samples (29) . This suggests that the human liver, sion like the rat liver, is also not a net producer of circulating rT3.
Thus, functionally, the liver acts more as an rT3 disposal organ or finding in the present study was that PTU, DEX, rather than a producer of rT3. idministration all produced significant elevations in Perhaps a more likely source of circulating rT3 would be 3 levels, but did so by different mechanisms. PTU, a from extrahepatic tissues where T4 to rT3 conversion is cataype I 5'-deiodinase inhibitor slowed the clearance of lyzed by the so-called type III or 5-deiodinase enzyme system. ch in turn, led to an increase in circulating rT3 and the Such a specific inner ring deiodinase system has been docuatio values without altering the daily rT3 production mented in rat skin, brain, and placenta as well as in the human . This is consistent with the previous work of Kaplan placenta (30) (31) (32) (33) . Whatever the specific tissue deiodinase sysvorkers who demonstrated that the administration of tem responsible for rT3 generation from T4 in man, it does not T4-replaced hypothyroid patients produced a similar appear to be inhibited by PTU since rT3 production rates were rum rT3 values (20) . These changes are also analogous not altered by the amount of PTU employed (1,200 mg/d). It lings previously described with fasting, liver disease, is of interest that such PTU dosages will inhibit 80% of outer thyroidal illnesses (13) (14) (15) (16) . DEX, a previously re-ring T4 deiodination in man (34) . Although the lack of PTU ype I 5'-deiodinase inhibitor, also increased the circu-inhibition in vivo is consistent with the observations in rat '3 and rT3/T4 ratio values (21) . However, this appeared brain and skin in vitro, a possible exception may exist in rat esult from decreased rT3 clearance, but rather from and human placenta where rT3 generation is inhibited (32, 33 DEX administration had no effect on rT3 clearance, but 0). did increase the total daily rT3 production rate. To our knowle were minor but important differences observed in edge, this is the first reported instance where increased levels of *ance and production rate estimates in euthyroid subcirculating rT3 resulted from augmented production rather ie mean normal rT3 plasma clearance rate of 157±22
than by decreased clearance. In turn, this suggests that DEX may directly stimulate the type III 5-deiodinase. The finding by Osathanondh and colleagues of an increase in amniotic fluid rT3 levels in pregnant women administered DEX is consistent with this observation (35) . However, McCann et al. were unable to show any influence ofcorticosterone acetate on the type III 5-deiodinase system in rat liver in vitro (36) . This may reflect either species variability or tissue specific regulation of type III 5-deiodinase enzyme activity. Both compartmental and noncompartmental analysis of mean serum rT3 tracer disappearance curves were performed in the present study. Computation of blood rT3 clearance rate estimates differed by < 10% using these two methods. More importantly, these differences did not alter the basic conclusions reached regarding the changes in the calculated rT3 production rates observed in the various study groups. Because of the multiple assumptions required for the compartmental approach (i.e., number of compartments, source of production, sites ofdegradation, so forth), noncompartmental analysis was used for calculation of the production estimates. Although compartmental analysis may potentially provide some information regarding the source of the increased rT3 production noted with glucocorticoid administration, without independent validation of this model separate from serum rT3 disappearance curves, such analysis would appear to be highly problematical.
The lack ofdetectable tracer rT3 in the urine as analyzed by HPLC was also a surprising finding. This phenomena was not due to breakdown ofrT3 as minimal degradation oflabeled rT3 occurred when added to fresh unlabeled urine samples that were incubated at 370C overnight. This observation is consistent with the findings of Rogowski and colleagues and Faber et al. who were unable to detect stable rT3 in urine using a specific radioimmunoassay (37, 38) . The lack of rT3 in urine may be due to either tubular reabsorption of filtered rT3 and/or rapid deiodination of rT3 by renal tubular 5'-deiodinase enzyme systems (39) . The predominance of 3,3'-T2 in the urinary thyronine metabolite fraction suggests that the tracer rT3 had been deiodinated, which is consistent with the observations in a perfused rat kidney where rapid deiodination of [1251]rT3 occurs with the identifiable urinary excretory products being iodide and 3,3',T2 (40) .
Another somewhat unexpected by-product was the minimal effect that PTU administration had on circulating T3 levels and T3/T4 ratio values in our subjects. This was surprising since PTU is known to inhibit the hepatic type I-5'-deiodinase system. This contrasts with other studies where dramatic falls in circulating T3 and T3/T4 ratios have occurred in subjects administered similar doses of PTU. Abuid and Larsen and Croxson et al. observed an 50% decrease in circulating T3 levels in hyperthyroid patients administered PTU (41, 42) . Further, Saberi et al. and Geffner and co-workers showed a less striking decrease of serum T3 in T4-replaced hypothyroid patients administered up to 1,000 mg of PTU per day (7, 8) . One possible explanation for the failure of serum T3 concentrations to fall in the present study may be due to a compensatory increase in TSH-mediated T3 secretion by the thyroid gland. However, this seems unlikely as serum TSH levels were only modestly but not significantly increased. Another interpretation would be that the source of circulating T3 varies with the level ofserum T4 concentration (43). Silva et al. have suggested that up to 40% ofthe circulating T3 in the adult rat is generated from the type II 5'-deiodinase pathway and that an even greater proportion is derived from this pathway in the neonatal rat (44, 45) . Similar estimates of T3 generation in the rat have also been made by DiStefano and colleagues employing kinetic models suggesting that 50% of the circulating T3 is derived from the so-called "slow pool" where type II 5'-deiodinase enzyme systems predominate (46) . DEX administration also produced lower serum T3 values, but did so in proportion to the decline in circulating T4 levels. This may reflect a vascular-tissue redistribution effect of DEX on T4 and T3 rather than an alteration in T4 to T3 conversion efficiency. This contrasts with the rapid fall in circulating T3 levels seen in thyrotoxic Graves' patients treated with DEX ( 11) . Thus, as with PTU, the effectiveness of DEX in lowering T3 levels may be related to the circulating T4 values. Supporting this view were the findings of Ferguson and Jennings who observed that a marked decrease in the conversion efficiency ofT4 to T3 could only be demonstrated when pharmacological doses ofT4 were employed in a perfused liver preparation from DEX-treated rats (47). Cavalieri et al. reported that whole body conversion rates of tracer T4 to T3 were reduced in intact T4-replaced hypothyroid rats treated with DEX (48) . However, these results were complicated by the unexpected alterations in the metabolism of tracer T3, including changes in T3 distribution and tissue binding as well as slowing of its clearance. This contrasts with the apparent lack of effect that DEX administration has on tracer T3 distribution and clearance in man (49) . Thus, it would appear that the intact rat and man may not be comparable models in studying the effects of glucocorticoids on peripheral thyroid hormone metabolism.
Clearly the present study revealed that peripheral rT3 metabolism in man is somewhat more complex than has been previously appreciated. Specifically, the source of circulating rT3 most likely orginates from extrahepatic tissues containing the type III 5-deiodinase, that the activity of this enzyme system is not influenced by PTU but stimulated by DEX, and that the proportion of T4 metabolized to circulating rT3 does not vary with substrate availability indicating that this is a low affinity, high capacity enzyme system.
